The drug cocktail reduced infections in a continuing late-stage study, the company reported
Regeneron Pharmaceuticals Inc. said its antibody drug reduced coronavirus infections by half in people at high risk, a preliminary sign the therapy could be given to temporarily prevent Covid-19.
None of the patients receiving the drug developed symptoms from the virus, Regeneron said Tuesday, providing an interim analysis of a continuing study.
Given the drug’s performance, Regeneron said it would discuss the possibility of authorizing the drug as a temporary vaccine with U.S. regulators. Complete trial data from the study is expected early in the second quarter, the company said.
Regeneron’s data indicate that antibody-based drugs could help provide temporary protection against Covid-19 as the U.S. and other countries grapple with limited supplies of vaccines. The drugs are thought to provide protection for at least one month.
Eli Lilly & Co. said last week that its antibody drug also prevented many infections in a study of nursing-home patients.